MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with ...

FUROSCIX is a registered trademark of scPharmaceuticals, a wholly owned subsidiary of MannKind Corporation. MANNKIND is a registered trademark of MannKind Corporation.
MPR

MannKind’s SubQ Furosemide Autoinjector Accepted for FDA Review

If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.
Drug Delivery Business

FDA accepts MannKind sNDA for autoinjector that treats edema

MannKind (Nasdaq:MNKD) announced that the FDA accepted a supplemental New Drug Application (sNDA) for its Furoscix ReadyFlow ...
Seeking Alpha

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

JUPITER, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (LGND) today announced that its partner SQ Innovation Inc. has received approval from the U.S. Food and Drug ...

MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients

MannKind Corporation beats Q3 estimates and sees FDA progress on ReadyFlow Autoinjector, presenting strong revenue growth potential. Learn more about MNKD stock here.
NBC4 Columbus

SQ Innovation Announces FDA Approval of Lasix® ONYU for Treatment of Edema in Heart Failure

BURLINGTON, Mass., Oct. 8, 2025 /PRNewswire/ -- SQ Innovation, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its drug-device combination Lasix ® ONYU (furosemide ...
Medscape

The Furosemide Diagnostic Test in Suspected Slow-onset Heart Failure

We performed PubMed searches for papers published from 1966 until September 2010, using the keywords: 'loop diuretic', 'furosemide', 'frusemide', 'weight loss', and 'diuretic test' with 'diagnosis', ...